Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUEL-Breast
NL-OMON60773Phase 2Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpelisib and fulvestrant in breast cancer, sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Progression-free survival. Started Jun 2022; status: active, not recruiting.
02
Drugs
alpelisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60773.